Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Crl
  6. /
  7. Stealth BioTherapeutics, Inc
CRL
•Stealth BioTherapeutics, Inc

Stealth BioTherapeutics, Inc – FDA CRL

Record Details

The FDA issued a Complete Response Letter (CRL) to Stealth BioTherapeutics Inc. for its New Drug Application (NDA 215244) concerning elamipretide injection, a treatment for Barth syndrome. The agency determined it could not approve the application due to several significant deficiencies, despite acknowledging the high unmet medical need for this rare disease.

The main issues involve the lack of established effectiveness for elamipretide under both traditional and accelerated approval pathways. For traditional approval, the primary randomized, placebo-controlled study (SPIBA-201 Part 1) did not demonstrate superiority for key clinical endpoints such as the 6-minute walk test and total fatigue score. Subsequent open-label and externally controlled studies (SPIBA-201 Part 2 and SPIBA-001) were found to be inadequate, primarily due to concerns about bias from effort-dependent endpoints, subjects' knowledge of treatment assignment, and significant methodological limitations, including issues with data reliability and statistical analysis.

For accelerated approval, the FDA deemed the proposed surrogate endpoints, including left ventricular stroke volume (LVSV), the MLCL:CL ratio, and acylcarnitines, unsuitable due to major limitations. While the 6-minute walk test is a direct measure for full approval, its effectiveness was not established. However, the FDA noted that muscle strength of the knee extensors, measured by handheld dynamometry, could potentially serve as an intermediate clinical endpoint for accelerated approval, outlining a potential path forward for this specific approach.

Finally, deficiencies were identified at the drug product manufacturing facility that must be resolved prior to any approval. Stealth BioTherapeutics Inc. must address these efficacy data shortcomings and manufacturing facility issues to proceed with the application.

Company
Stealth BioTherapeutics, Inc
Product type
NDA (New Drug Application)
Person
  • Jim Carr
View Company Profile

ID · 928efdea-4fa4-4665-b37a-50323310343f

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Stealth BioTherapeutics, Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.